Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: June 2007
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Teva Pharmaceutical Industries Ltd. et. al. v. Zentiva, S.A.1:07-cv-21593; filed June 21, 2007 in the Southern District of Florida Declaratory judgment of…
-
By Mark Chael — As Patent Docs has previously reported (here and here), the USPTO recently held a customer partnership meeting for the biotech, chemical, and pharmaceutical art groups. Of the many interesting and informative presentations and discussions from the meeting, those of us that prosecute patent applications directed to oligonucleotide, protein, and…
-
June 26-28, 2007 – Euro-Biotech Forum 2007 – Paris, France June 28, 2007 – "Patent Licensing Post MedImmune: Proceed with Caution: Best Practices for Adapting to Sweeping Change in Licensing" (Strafford CLE Teleconferences) July 12-14, 2007 – Intellectual Property Law Summer Institute (Institute of Continuing Legal Education) – Mackinac Island, Michigan July 16-17, 2007 –…
-
By Mark Chael — The Nasdaq Stock Market, Inc. recently announced that as part of its semi-annual re-ranking of the NASDAQ Biotechnology Index® (NBI), thirteen securities have been added to the index, while four have been dropped. All of the securities on the NBI are classified as biotech or pharma according to the…
-
By Kevin E. Noonan — Federal District Court Judge Patti Saris handed down her decision in a major class action suit against several pharmaceutical companies, and the pharmaceutical companies cannot be happy with the result. In re Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, Civil Action No. 01-12257-PBS (D. Mass. 2007).…
-
By Kevin E. Noonan — U.S. patent practitioners have long felt that obtaining patent protection in Japan was more difficult than in other countries, particularly for biotechnology inventions. An article in Nature Biotechnology last month (Aida et al., "Shortened life spans of biotech pioneer patents in Japan: a lesson from the DNA chip")…
-
By Kevin E. Noonan — The U.S. faces a potential crisis over the failure of the Food and Drug Administration (FDA) to properly oversee quality assurance for drugs produced by foreign generic drug companies. The risks of the current situation, detailed in an earlier post (see "The Effect of Foreign Generics on The…
-
By Donald Zuhn — On Monday, the European Patent Office (EPO) announced that patent filings rose by 5% in 2006, jumping from 197,400 in 2005 to 207,300 in 2006. While the proportion of filings originating from the 32 EPO member states fell from 49.6% to 48.5%, the number of filings originating from the…
-
By Donald Zuhn — Sanofi-Aventis and Bristol-Myers Squibb announced today (June 19, 2007) that the U.S. District Court for the Southern District of New York has issued a ruling in their favor in an infringement action against Apotex. Sanofi and BMS filed the action in March of 2002, contending that Apotex’ filing of…
-
By Kevin E. Noonan — In the face of increases in the numbers of medications available to treat ailments from the life-threatening to the annoying (or, in the case of Viagra®, embarrassing), the numbers of prescriptions taken per person, particularly the elderly, and the costs of these drugs, there is a concomitantly increased…
Patent Docs 